MedPageToday -- Patients with heavily pretreated breast cancer gained more than two months of life with the microtubule inhibitor eribulin (Halaven) compared with a treatment of physician choice, final results of a large randomized trial showed. Women receiving eribulin had a median overall survival of 13.1 months compared with 10.6 months for the control arm.
